

Supplementary tables:**Table S1.** Change in particle size of benzocaine in ointment prepared on Pentravan® base, depending on storage time.

Formulation code	Time [days]	Percentage of individual benzocaine particles in the sample [%]				P≤
		<30µm	31-60µm	61-90µm	>91µm	
P-1	after preparation	72.50 ± 0.67	16.83 ± 0.83	9.00 ± 0.67	1.67 ± 0.78	
	7	70.00 ± 0.67	26.50 ± 0.67	3.33 ± 0.44	0.33 ± 0.44	
	14	68.50 ± 0.50	17.83 ± 0.56	12.00 ± 0.33	1.67 ± 0.44	
	21	66.33 ± 0.78	19.67 ± 0.78	12.00 ± 0.67	2.00 ± 0.33	
	28	58.83 ± 0.56*	25.00 ± 0.67*	7.83 ± 0.56*	8.33 ± 0.44*	0.01
P-2	after preparation	78.33 ± 0.67	19.67 ± 0.78	2.00 ± 0.67	0.17 ± 0.28	
	7	74.50 ± 0.83	21.83 ± 0.89	4.17 ± 0.56	0.17 ± 0.28	
	14	71.67 ± 0.78	24.67 ± 1.22	3.67 ± 0.56	0.00 ± 0.00	
	21	68.00 ± 1.00	24.67 ± 1.89	7.33 ± 1.89	0.00 ± 0.00	
	28	62.33 ± 0.78*	23.67 ± 1.11*	9.33 ± 1.00*	4.67 ± 1.33*	0.01
P-3	after preparation	82.17 ± 1.22	16.17 ± 0.61	1.67 ± 0.78	0.00 ± 0.00	
	7	92.00 ± 1.20	6.00 ± 0.80	2.00 ± 0.80	0.00 ± 0.00	
	14	80.83 ± 1.17	17.33 ± 1.33	1.83 ± 0.89	0.00 ± 0.00	
	21	82.67 ± 1.22	13.17 ± 1.50	4.17 ± 0.89	0.00 ± 0.00	
	28	69.83 ± 2.22*	24.67 ± 1.00*	5.50 ± 1.50*	0.00 ± 0.00	0.01
P-4	after preparation	9.83 ± 1.22	6.00 ± 1.00	2.00 ± 1.00	0.00 ± 0.00	
	7	89.17 ± 0.89	8.00 ± 0.33	2.83 ± 0.89	0.00 ± 0.00	
	14	86.17 ± 0.89	9.50 ± 1.33	4.00 ± 1.00	0.00 ± 0.00	
	21	86.83 ± 1.50	10.17 ± 0.93	3.67 ± 1.33	0.00 ± 0.00	
	28	75.33 ± 1.00*	20.00 ± 0.67*	4.50 ± 1.50*	0.00 ± 0.00	0.01
P-5	after preparation	95.67 ± 0.78	4.33 ± 0.78	0.00 ± 0.00	0.00 ± 0.00	
	7	92.00 ± 1.00	8.00 ± 1.00	0.00 ± 0.00	0.00 ± 0.00	
	14	92.67 ± 0.89	7.67 ± 0.89	0.00 ± 0.00	0.00 ± 0.00	
	21	93.00 ± 0.67	5.50 ± 0.67	1.50 ± 0.83	0.00 ± 0.00	
	28	89.83 ± 1.56*	10.17 ± 1.56*	0.00 ± 0.00	0.00 ± 0.00	0.01
P-6	after preparation	96.00 ± 1.33	4.00 ± 1.33	0.00 ± 0.00	0.00 ± 0.00	
	7	94.00 ± 2.00	6.00 ± 1.67	0.00 ± 0.00	0.00 ± 0.00	
	14	94.33 ± 1.67	6.17 ± 1.50	0.00 ± 0.00	0.00 ± 0.00	
	21	93.83 ± 0.89	6.17 ± 0.89	0.00 ± 0.00	0.00 ± 0.00	
	28	91.83 ± 1.83*	6.33 ± 1.67*	1.83 ± 0.89	0.00 ± 0.00	0.01
P-7	after preparation	88.00 ± 1.33	10.00 ± 1.67	2.00 ± 1.00	0.00 ± 0.00	
	7	83.60 ± 1.68	14.17 ± 1.22	2.00 ± 1.00	0.00 ± 0.00	
	14	85.17 ± 1.50	15.83 ± 1.17	2.00 ± 0.67	0.00 ± 0.00	
	21	76.00 ± 2.00	20.00 ± 2.00	4.00 ± 1.00	0.00 ± 0.00	
	28	72.50 ± 2.33*	24.67 ± 1.67*	4.17 ± 0.89	0.00 ± 0.00	0.01
P-8	after preparation	88.17 ± 1.50	11.83 ± 1.50	0.00 ± 0.00	0.00 ± 0.00	
	7	85.83 ± 1.89	14.17 ± 1.89	0.00 ± 0.00	0.00 ± 0.00	
	14	82.00 ± 1.33	18.00 ± 1.33	0.00 ± 0.00	0.00 ± 0.00	
	21	79.67 ± 1.67	18.33 ± 2.00	2.00 ± 0.67	0.00 ± 0.00	
	28	75.83 ± 2.17*	18.17 ± 1.56*	2.00 ± 1.00*	4.00 ± 1.00	0.01

* Statistically significant (p≤0.01) compared to the sample immediately after preparation; n=6; M=mean; SD=standard deviation

Table S 2. Change in particle size of benzocaine in ointment prepared on Lekobaza base, depending on storage time.

Formulation code	Time [days]	Percentage of individual benzocaine particles in the sample [%]				P≤
		<30µm	31-60µm	61-90µm	>91µm	
L-9	after preparation	87.33 ± 1.33	10.83 ± 1.17	1.83 ± 0.56	0.00 ± 0.00	
	7	80.17 ± 0.89	16.00 ± 1.16	3.83 ± 0.89	0.00 ± 0.00	
	14	77.17 ± 2.50	20.00 ± 2.00	4.00 ± 0.67	0.00 ± 0.00	
	21	63.83 ± 1.17	31.83 ± 2.22	2.33 ± 1.00	2.00 ± 1.00	
	28	63.67 ± 2.44*	26.00 ± 2.00*	8.33 ± 1.78*	2.00 ± 1.00	0.01
L-10	after preparation	88.00 ± 1.00	12.00 ± 1.00	0.00 ± 0.00	0.00 ± 0.00	
	7	84.67 ± 1.22	8.17 ± 1.50	6.33 ± 1.33	1.83 ± 0.89	
	14	81.17 ± 1.11	14.67 ± 0.78	2.33 ± 0.78	1.86 ± 0.89	
	21	67.83 ± 1.83	22.17 ± 1.22	4.00 ± 0.67	6.00 ± 1.00	
	28	68.50 ± 2.17*	25.17 ± 1.50*	4.17 ± 1.22	2.00 ± 1.00	0.01
L-11	after preparation	94.00 ± 1.00	6.00 ± 1.00	0.00 ± 0.00	0.00 ± 0.00	
	7	93.83 ± 0.83	6.17 ± 0.89	0.00 ± 0.00	0.00 ± 0.00	
	14	85.50 ± 1.00	12.17 ± 0.89	2.33 ± 0.44	0.00 ± 0.00	
	21	77.67 ± 1.33	18.17 ± 1.17	4.17 ± 0.56	0.00 ± 0.00	
	28	75.67 ± 1.33*	20.17 ± 0.89*	4.17 ± 0.56	0.00 ± 0.00	0.01
L-12	after preparation	96.17 ± 0.89	4.00 ± 1.00	0.00 ± 0.00	0.00 ± 0.00	
	7	96.25 ± 0.72	4.33 ± 0.78	0.00 ± 0.00	0.00 ± 0.00	
	14	92.67 ± 2.57	6.17 ± 1.17	1.83 ± 0.89	0.00 ± 0.00	
	21	80.17 ± 2.89	13.83 ± 1.56	4.00 ± 1.00	2.00 ± 1.00	
	28	85.00 ± 3.00*	10.67 ± 1.67*	2.33 ± 0.78	2.00 ± 1.00	0.01
L-13	after preparation	88.80 ± 1.44	11.50 ± 1.50	0.00 ± 0.00	0.00 ± 0.00	
	7	75.50 ± 1.83	18.17 ± 1.83	6.33 ± 1.00	0.00 ± 0.00	
	14	86.17 ± 2.17	11.83 ± 1.22	2.00 ± 1.00	0.00 ± 0.00	
	21	68.67 ± 2.00	23.67 ± 1.44	7.67 ± 1.44	0.00 ± 0.00	
	28	64.00 ± 2.00*	31.83 ± 1.56*	4.17 ± 1.56	0.00 ± 0.00	0.01

* Statistically significant (p≤0.01) compared to the sample immediately after preparation; n=6; M-mean; SD-standard deviation

Table S3. Change in particle size of benzocaine in ointment prepared on Lekobaza LUX base, depending on storage time.

Formulation code	Time [days]	Percentage of individual benzocaine particles in the sample [%]				P≤
		<30µm	31-60µm	61-90µm	>91µm	
LLux-14	after preparation	89.60 ± 1.92	8.50 ± 1.50	1.83 ± 1.17	0.00 ± 0.00	
	7	90.33 ± 1.67	5.67 ± 1.56	4.00 ± 1.00	0.00 ± 0.00	
	14	89.67 ± 1.78	6.00 ± 1.00	4.33 ± 0.78	0.00 ± 0.00	
	21	85.83 ± 1.17	12.00 ± 1.33	2.17 ± 0.89	0.00 ± 0.00	
	28	80.00 ± 2.00*	18.00 ± 3.00*	2.00 ± 1.00*	0.00 ± 0.00	0.01
LLux -15	after preparation	94.17 ± 0.89	5.83 ± 0.89	0.00 ± 0.00	0.00 ± 0.00	
	7	91.33 ± 1.00	6.83 ± 1.50	1.83 ± 0.89	0.00 ± 0.00	
	14	81.83 ± 3.44	17.83 ± 1.17	2.00 ± 0.67	0.00 ± 0.00	
	21	88.00 ± 1.20	12.00 ± 1.00	0.00 ± 0.00	0.00 ± 0.00	
	28	85.83 ± 0.61*	8.50 ± 1.50*	5.67 ± 1.00	0.00 ± 0.00	0.01
LLux -16	after preparation	95.17 ± 1.22	5.83 ± 1.17	0.00 ± 0.00	0.00 ± 0.00	
	7	94.00 ± 1.67	6.00 ± 1.67	0.00 ± 0.00	0.00 ± 0.00	
	14	90.83 ± 3.50	8.00 ± 1.00	1.83 ± 0.89	0.00 ± 0.00	
	21	89.67 ± 3.00	8.33 ± 2.00	2.00 ± 1.00	0.00 ± 0.00	
	28	87.67 ± 1.44*	8.50 ± 1.50*	3.83 ± 0.89	0.00 ± 0.00	0.01
LLux -17	after preparation	96.33 ± 1.33	3.67 ± 1.33	0.00 ± 0.00	0.00 ± 0.00	
	7	94.33 ± 0.78	5.67 ± 0.78	0.00 ± 0.00	0.00 ± 0.00	
	14	92.17 ± 1.17	7.83 ± 1.17	0.00 ± 0.00	0.00 ± 0.00	
	21	98.00 ± 1.00	2.00 ± 1.00	0.00 ± 0.00	0.00 ± 0.00	
	28	92.23 ± 1.33*	7.67 ± 1.33*	0.00 ± 0.00	0.00 ± 0.00	0.01
LLux -18	after preparation	92.17 ± 1.17	7.83 ± 1.17	0.00 ± 0.00	0.00 ± 0.00	
	7	92.00 ± 1.67	6.00 ± 1.00	2.00 ± 1.00	0.00 ± 0.00	
	14	89.83 ± 1.22	7.83 ± 1.17	2.33 ± 0.78	0.00 ± 0.00	
	21	89.83 ± 1.50	7.67 ± 1.00	2.50 ± 1.17	0.00 ± 0.00	
	28	92.17 ± 1.83	7.83 ± 1.83	0.00 ± 0.00	0.00 ± 0.00	

* Statistically significant (p≤0.01) compared to the sample immediately after preparation; n=6; M-mean; SD-standard deviation

Table S4. Change in particle size of benzocaine in ointment prepared on Euceryna base, depending on storage time.

Formulation code	Time [days]	Percentage of individual benzocaine particles in the sample [%]				P≤
		<30µm	31-60µm	61-90µm	>91µm	
E-19	after preparation	47.67 ± 1.11	17.83 ± 1.56	10.67 ± 2.00	23.83 ± 2.22	
	7	44.17 ± 1.83	22.33 ± 1.11	11.83 ± 1.17	21.67 ± 1.33	
	14	42.00 ± 1.00	28.33 ± 1.44	13.17 ± 1.17	18.17 ± 1.83	
	21	40.33 ± 1.44	25.83 ± 0.89	20.00 ± 1.00	14.33 ± 1.00	
	28	38.17 ± 1.17*	30.17 ± 0.89*	15.50 ± 1.50*	16.00 ± 0.67*	0.01
E-20	after preparation	49.00 ± 2.33	26.00 ± 1.00	10.17 ± 0.89	14.17 ± 1.17	
	7	46.00 ± 1.33	23.67 ± 1.44	14.17 ± 1.22	16.17 ± 1.22	
	14	43.83 ± 2.56	32.00 ± 1.00	13.83 ± 1.56	10.33 ± 0.78	
	21	43.67 ± 1.11	32.00 ± 1.00	12.50 ± 1.50	11.83 ± 1.22	
	28	44.00 ± 2.67*	23.83 ± 1.17	20.17 ± 1.17*	12.00 ± 1.00*	0.01
E-21	after preparation	85.83 ± 0.83	14.17 ± 0.83	0.00 ± 0.00	0.00 ± 0.00	
	7	81.50 ± 1.17	14.33 ± 0.67	4.17 ± 0.89	0.00 ± 0.00	
	14	79.50 ± 0.83	18.17 ± 0.56	2.33 ± 0.44	0.00 ± 0.00	
	21	77.67 ± 0.67	20.17 ± 0.56	2.17 ± 0.56	0.00 ± 0.00	
	28	73.67 ± 0.78*	18.17 ± 0.89*	8.17 ± 0.56	0.00 ± 0.00	0.01
E-22	after preparation	89.67 ± 1.11	8.17 ± 0.56	2.17 ± 0.56	0.00 ± 0.00	
	7	85.67 ± 0.11	10.17 ± 1.17	4.17 ± 0.56	0.00 ± 0.00	
	14	83.83 ± 0.89	16.17 ± 0.89	0.00 ± 0.00	0.00 ± 0.00	
	21	83.67 ± 1.11	12.17 ± 0.89	4.17 ± 0.89	0.00 ± 0.00	
	28	77.67 ± 1.44*	14.17 ± 0.89*	8.17 ± 0.89*	0.00 ± 0.00	0.01
E-23	after preparation	93.83 ± 0.56	6.17 ± 0.56	0.00 ± 0.00	0.00 ± 0.00	
	7	86.33 ± 3.56	8.17 ± 0.89	2.17 ± 0.89	0.00 ± 0.00	
	14	89.50 ± 1.33	6.33 ± 0.78	4.17 ± 0.89	0.00 ± 0.00	
	21	91.83 ± 0.89	8.17 ± 0.89	0.00 ± 0.00	0.00 ± 0.00	
	28	87.67 ± 0.79*	6.17 ± 0.89	6.17 ± 0.89	0.00 ± 0.00	0.01
E-24	after preparation	97.83 ± 0.89	2.17 ± 0.89	0.00 ± 0.00	0.00 ± 0.00	
	7	93.83 ± 0.89	6.17 ± 0.89	0.00 ± 0.00	0.00 ± 0.00	
	14	91.83 ± 0.89	8.17 ± 0.89	0.00 ± 0.00	0.00 ± 0.00	
	21	93.67 ± 0.44	4.17 ± 0.56	2.17 ± 0.89	0.00 ± 0.00	
	28	90.67 ± 0.67*	9.33 ± 0.67*	0.00 ± 0.00	0.00 ± 0.00	0.01

* Statistically significant (p≤0.01) compared to the sample immediately after preparation; n=6; M=mean; SD=standard deviation

Table S5. Change in particle size of benzocaine in ointment prepared on Nourivan™ Antiox or Fitalite™ base, depending on storage time.

Formulation code	Time [days]	Percentage of individual benzocaine particles in the sample [%]				P≤
		<30µm	31-60µm	61-90µm	>91µm	
N-25	after preparation	73.33 ± 1.89	22.17 ± 1.17	2.17 ± 0.89	2.00 ± 0.67	
	7	67.50 ± 1.50	28.17 ± 0.89	2.17 ± 0.89	2.17 ± 0.56	
	14	69.50 ± 1.50	28.17 ± 0.89	2.33 ± 1.11	0.00 ± 0.00	
	21	70.83 ± 0.83	17.67 ± 1.00	11.50 ± 1.00	0.00 ± 0.00	
	28	59.33 ± 2.22*	20.33 ± 1.33	14.17 ± 1.22*	6.17 ± 0.89*	0.01
N-26	after preparation	79.33 ± 2.89	18.33 ± 2.11	2.33 ± 0.78	0.00 ± 0.00	
	7	73.67 ± 1.33	22.17 ± 0.83	4.17 ± 0.89	0.00 ± 0.00	
	14	75.67 ± 1.44	20.17 ± 1.17	4.17 ± 1.22	0.00 ± 0.00	
	21	77.67 ± 1.78	12.17 ± 0.89	10.17 ± 1.22	0.00 ± 0.00	
	28	65.50 ± 0.83*	16.17 ± 0.89*	16.17 ± 0.56*	2.17 ± 0.89	0.01
F-27	after preparation	75.67 ± 1.78	18.17 ± 1.17	6.17 ± 0.89	0.00 ± 0.00	
	7	69.67 ± 1.33	24.17 ± 1.17	6.17 ± 0.89	0.00 ± 0.00	
	14	67.67 ± 1.00	26.17 ± 0.56	6.17 ± 0.89	0.00 ± 0.00	
	21	60.33 ± 2.44	19.83 ± 1.83	17.83 ± 1.17	2.00 ± 1.00	
	28	35.83 ± 1.17*	45.83 ± 0.89*	14.17 ± 1.22*	4.17 ± 1.22	0.01
F-28	after preparation	75.67 ± 1.44	22.17 ± 0.89	2.17 ± 0.89	0.00 ± 0.00	
	7	71.67 ± 1.78	22.17 ± 1.17	6.17 ± 0.89	0.00 ± 0.00	
	14	69.50 ± 1.77	24.17 ± 0.89	6.33 ± 0.78	0.00 ± 0.00	
	21	67.67 ± 1.78	18.33 ± 1.78	14.00 ± 1.00	0.00 ± 0.00	
	28	62.00 ± 1.33*	18.17 ± 0.89*	17.83 ± 0.56*	2.00 ± 1.00	0.01

* Statistically significant ($p \leq 0.01$) compared to the sample immediately after preparation; n=6; M-mean; SD-standard deviation

Table S6. Change in benzocaine particle size in emulsion ointments depending on the used base and storage time.

Formulation code	Time [days]	Percentage of individual benzocaine particles in the sample [%]			
		<30µm	31-60µm	61-90µm	>91µm
P-E-29	after preparation	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	7	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	14	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	21	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	28	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
P-E-30	after preparation	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	7	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	14	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	21	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	28	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
L-E-31	after preparation	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	7	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	14	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	21	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	28	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
L-E-32	after preparation	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	7	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	14	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	21	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	28	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
LLX-E-33	after preparation	rw*	rw	rw	rw
	7	rw	rw	rw	rw
	14	rw	rw	rw	rw
	21	rw	rw	rw	rw
	28	rw	rw	rw	rw
LLX-E-34	after preparation	rw	rw	rw	rw
	7	rw	rw	rw	rw
	14	rw	rw	rw	rw
	21	rw	rw	rw	rw
	28	rw	rw	rw	rw
E-E-35	after preparation	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	7	100.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	14	80.00 ± 1.00	12.00 ± 1.00	0.00 ± 0.00	0.00 ± 0.00
	21	92.00 ± 1.00	6.33 ± 1.11	1.67 ± 0.78	0.00 ± 0.00
	28	76.17 ± 0.89	17.83 ± 1.22	4.00 ± 1.00	2.00 ± 0.33
E-E-36	after preparation	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	7	94.50 ± 1.50	5.50 ± 1.50	0.00 ± 0.00	0.00 ± 0.00
	14	86.00 ± 1.00	12.00 ± 0.33	2.00 ± 0.67	0.00 ± 0.00
	21	76.83 ± 1.17	15.83 ± 0.28	7.33 ± 1.00	0.00 ± 0.00
	28	68.83 ± 0.89	20.00 ± 1.00	4.33 ± 0.78	7.83 ± 0.89
N-E-37	after preparation	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	7	100.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	14	98.29 ± 0.78	1.71 ± 0.78	0.00 ± 0.00	0.00 ± 0.00
	21	96.50 ± 0.83	3.67 ± 0.78	0.00 ± 0.00	0.00 ± 0.00
	28	94.17 ± 0.56	5.83 ± 0.56	0.00 ± 0.00	0.00 ± 0.00
N-E-38	after preparation	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	7	98.00 ± 0.67	2.00 ± 0.67	0.00 ± 0.00	0.00 ± 0.00
	14	97.83 ± 0.56	2.17 ± 0.56	0.00 ± 0.00	0.00 ± 0.00
	21	92.17 ± 0.89	7.83 ± 0.89	0.00 ± 0.00	0.00 ± 0.00

	28	90.00 ± 1.00	10.00 ± 1.00	0.00 ± 0.00	0.00 ± 0.00
F-E-39	after preparation	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	7	100 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	14	92.00 ± 1.00	7.83 ± 0.83	0.00 ± 0.00	0.00 ± 0.00
	21	89.83 ± 1.22	10.17 ± 1.22	0.00 ± 0.00	0.00 ± 0.00
	28	88.55 ± 1.50	9.67 ± 1.67	1.83 ± 0.56	0.00 ± 0.00
F-E-40	after preparation	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	7	97.83 ± 0.56	2.17 ± 0.56	0.00 ± 0.00	0.00 ± 0.00
	14	87.83 ± 0.89	12.17 ± 0.89	0.00 ± 0.00	0.00 ± 0.00
	21	8.83 ± 1.17	18.17 ± 1.17	0.00 ± 0.00	0.00 ± 0.00
	28	86.00 ± 1.00	10.00 ± 1.33	4.00 ± 0.33	0.00 ± 0.00

* Statistically significant ($p \leq 0.01$) compared to the sample immediately after preparation; n=6; M=mean; SD=standard deviation.